ALT - Altimmune, Inc.
NEXT EARNINGS:
Feb 26, 2026
(in 1 day)
EPS Est: $-0.25
|
Rev Est: $560
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$20.00
DETAILS
HIGH:
$20.00
LOW:
$20.00
MEDIAN:
$20.00
CONSENSUS:
$20.00
UPSIDE:
337.64%
Market Cap:
403.34M
Volume:
2,933,098
Avg Volume:
4,942,663
52 Week Range:
2.9-7.73
Sector:
Healthcare
Industry:
Biotechnology
Beta:
0.08
Last Dividend:
$N/A
Exchange:
NASDAQ
Country:
US
Employees:
59
IPO Date:
2017-05-26
EPS (TTM):
-1.34
P/E Ratio:
-5.39
Revenue (TTM):
20,000
Total Assets:
139.31M
Total Debt:
1.68M
Cash & Equiv:
36.93M
Rev Growth (5Y):
-67.8%
EPS Growth (5Y):
N/A
FCF Growth (5Y):
N/A
ROCE:
-73.8%
Debt/Equity:
0.01
Earnings History
| Date | EPS Actual | EPS Est | EPS Surprise | Rev Actual | Rev Est | Rev Surprise |
|---|---|---|---|---|---|---|
| 2025-11-06 | $-0.21 | $-0.29 | +27.6% | $5000 | $560 | +792.9% |
| 2025-08-12 | $-0.27 | $-0.32 | +15.6% | $5000 | $1429 | +249.9% |
| 2025-05-13 | $-0.26 | $-0.35 | +25.7% | $5000 | $560 | +792.9% |
| 2025-02-27 | $-0.33 | $-0.34 | +2.9% | $5000 | $1000 | +400.0% |
| 2024-11-12 | $-0.32 | $-0.36 | +11.1% | $5000 | $714 | +600.3% |
| 2024-08-08 | $-0.35 | $-0.34 | -2.9% | $5000 | $714 | +600.3% |
| 2024-05-09 | $-0.34 | $-0.36 | +5.6% | $5000 | — | — |
| 2024-03-27 | $-0.33 | $-0.35 | +5.7% | $37000 | $2143 | +1626.6% |
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 20,000 | 426,000 | (68,000) | 4.41M | 8.19M | 5.80M | 10.33M | 41,503 | 5.23M | 10.64M | 10.19M | 17.91M |
| Net Income | (95.06M) | (88.45M) | (84.71M) | (97.09M) | (49.04M) | (20.52M) | (39.17M) | (46.43M) | 193.85M | (3.44M) | (9.96M) | (11.72M) |
| EPS | -1.34 | -1.66 | -1.81 | -2.35 | -1.91 | -1.56 | -13.98 | -108.77 | -49.80 | -16.13 | -51.91 | -69.40 |
| Total Assets | 139.31M | 210.64M | 206.93M | 218.87M | 245.12M | 54.06M | 54.75M | 63.03M | 224.74M | 19.86M | 21.98M | 17.14M |
| Total Debt | 1.68M | 671,000 | 1.12M | 1.53M | 1.82M | 1.74M | 572,770 | 49,702 | 984,580 | 1.08M | 746,146 | 2.82M |
| Cash & Equivalents | 36.93M | 135.12M | 111.10M | 190.30M | 115.92M | 8.96M | 33.72M | 8.77M | 153.99M | 15.57M | 18.64M | 10.48M |
| Operating Cash Flow | (79.85M) | (75.81M) | (62.59M) | (78.24M) | (34.31M) | (9.60M) | (9.39M) | (20.21M) | 201.51M | (3.22M) | (8.47M) | (7.17M) |
| Free Cash Flow | (79.85M) | (75.86M) | (62.71M) | (90.55M) | (34.65M) | (9.60M) | (10.40M) | (20.38M) | 201.48M | (3.30M) | (8.57M) | (7.25M) |
| FCF per Share | -1.12 | -1.42 | -1.34 | -2.19 | -1.35 | -0.73 | -3.71 | -47.75 | 874.54 | -15.48 | -44.67 | -42.95 |
| Book Value | 123.51M | 194.10M | 185.29M | 199.13M | 225.88M | 45.52M | 48.31M | 48.68M | 19.46M | 16.65M | 18.27M | 7.34M |
| Cash & ST Investments | 131.89M | 197.81M | 184.88M | 190.30M | 215.92M | 37.24M | 33.72M | 8.77M | 220.81M | 15.57M | 18.64M | 10.48M |
| ROC Equity | -0.77 | -0.46 | -0.46 | -0.49 | -0.22 | -0.45 | -0.81 | -0.95 | 9.96 | -0.21 | -0.54 | -1.60 |